Pliant Therapeutics' Drug Trial Shows Promise In Reversing Lung Fibrosis In Patients
Pliant Therapeutics' Drug Trial Shows Promise In Reversing Lung Fibrosis In Patients
On Tuesday, Pliant Therapeutics Inc (NASDAQ:PLRX) announced topline data from a Phase 2a PET Imaging trial of bexotegrast (PLN-74809) evaluating change in total collagen levels in the lungs of patients with idiopathic pulmonary fibrosis (IPF) characterized by excessive collagen deposition in the lung.
週二，Pliant Therapeutics Inc（納斯達克股票代碼：PLRX）公佈了bexotegrast（PLN-74809）2a期PET成像試驗的主要數據，該試驗評估了以肺部膠原蛋白沉積過多爲特徵的特發性肺纖維化（IPF）患者肺部膠原蛋白總水平的變化。
Bexotegrast-treated patients showed reduced total lung collagen post-treatment as measured by positron emission tomography (PET) imaging, compared to increased total lung collagen in the placebo group, suggesting potential reversal of fibrosis.
與安慰劑組的肺膠原蛋白總量增加相比，通過正電子發射斷層掃描（PET）成像測量，接受Bexotegrast治療的患者在治療後肺部膠原蛋白總量減少，這表明纖維化可能逆轉。
After 12 weeks of treatment, bexotegrast-treated patients showed a reduction in standardized uptake value (SUV) of 68GA-CBP8 in the lung compared to an increase in placebo.
經過12周的治療，與安慰劑的增加相比，接受bexotegrast治療的患者肺中 68GA-CBP8 的標準攝取值（SUV）有所降低。
68GA-CBP8 is a PET ligand that binds to type 1 collagen.
68GA-CBP8 是一種與 1 型膠原蛋白結合的 PET 配體。
This reduction in SUV indicates reduced total lung collagen in the treated group, suggesting a potential reversal of fibrosis.
SUV的減少表明接受治療組的肺部膠原蛋白總量減少，這表明纖維化有可能逆轉。
Bexotegrast-treated patients demonstrated improvements in forced vital capacity (FVC) and reduced cough severity compared to placebo.
與安慰劑相比，接受Bexotegrast治療的患者表現出強迫肺活量（FVC）的改善和咳嗽的嚴重程度降低。
The trial's exploratory efficacy endpoints assessed changes in FVC forced vital capacity percent predicted (FVCpp), patient-reported cough severity, and fibrosis biomarkers.
該試驗的探索性療效終點評估了FVC強制肺活量預測百分比（fvCPP）、患者報告的咳嗽嚴重程度和纖維化生物標誌物的變化。
Bexotegrast-treated patients experienced improved lung function, as measured by FVC and FVCpp, with a clear separation from placebo.
根據FVC和fvCPP的測量，接受Bexotegrast治療的患者的肺功能得到改善，與安慰劑明顯分開。
Across all time points, bexotegrast-treated patients experienced reduced patient-reported cough severity compared to placebo patients.
在所有時間點上，與安慰劑患者相比，接受bexotegrast治療的患者報告的咳嗽嚴重程度有所降低。
At weeks 4 and 12, bexotegrast-treated patients demonstrated a reduction in circulating biomarkers integrin beta-6 and PRO-C3 relative to placebo.
在第 4 周和第 12 周，與安慰劑相比，經過 bexotegrat 治療的患者表現出循環生物標誌物整合素 β-6 和 PRO-C3 的含量有所減少。
PRO-C3, a serum biomarker of type III collagen synthesis, is elevated in patients with IPF and associated with progressive disease.
PRO-C3 是 III 型膠原蛋白合成的血清生物標誌物，在 IPF 患者中升高，與進行性疾病有關。
Bexotegrast was well tolerated at 160 mg over 12 weeks of treatment, with no serious adverse events reported.
在12周的治療中，160毫克的Bexotegrast耐受性良好，沒有報告嚴重的不良事件。
Most frequently reported treatment-emergent adverse events were mild in severity with no trial discontinuations.
最常報告的治療緊急不良事件的嚴重程度較輕，沒有中止試驗。
Price Action: PLRX shares are up 1.3% at $13.90 at last check Tuesday.
價格走勢：週二最後一次檢查時，PLRX股價上漲1.3％，至13.90美元。
Photo: Shutterstock
照片：Shutterstock